Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share

About this update from Hemostemix Inc

[{"type":"text","content":"Hemostemix Closes Private Placement of USD $336,500 at $0.295 per ShareCalgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\"), per the Company's February 4, 2025 news release, closed the previously announced USD $336,500 non-brokered private placement, issuing 1,634,466 Common Shares at CAD $0.295 each to CytoImmune Therapeutics LLC, following the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. Per Policy 4.1., Cytoimmune Therapeutics LLC is arm's length to the Company and is not a Related Party to the Company at the time of disclosure.The use of proceeds will be allocated to general working capital purposes, including business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.For further information, please contact: Thomas Smeenk, President, CEO & Co-FounderEM: [email protected] PH: 905-580-4170Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies o...

More updates from Hemostemix Inc